
Covetrus Revenue | CVET
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Covetrus
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 4.58 B | 4.34 B | 3.98 B | 3.78 B | 3.58 B | 3.35 B | 2.98 B | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.58 B | 2.98 B | 3.8 B |
Quarterly Revenue Covetrus
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 1.22 B | 1.15 B | - | 1.16 B | 1.19 B | 1.1 B | 1.12 B | 1.13 B | 1.03 B | 1.06 B | 1.01 B | 1.02 B | 1.01 B | 941 M | 903 M | 923 M | 1 B | 947 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.22 B | 903 M | 1.05 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Health information services industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
1Life Healthcare
ONEM
|
1.05 B | - | - | $ 3.37 B | ||
|
R1 RCM
RCM
|
1.47 B | - | - | $ 3.81 B | ||
|
Tabula Rasa HealthCare
TRHC
|
300 M | - | - | $ 255 M | ||
|
Change Healthcare
CHNG
|
3.48 B | - | - | $ 9.03 B | ||
|
Cerner Corporation
CERN
|
5.76 B | - | - | $ 27.9 B | ||
|
Accolade
ACCD
|
414 M | - | 0.29 % | $ 206 M | ||
|
NantHealth
NH
|
67 M | - | -46.64 % | $ 10.4 M | ||
|
10x Genomics
TXG
|
643 M | $ 57.05 | 1.33 % | $ 7.12 B | ||
|
Signify Health
SGFY
|
184 M | - | -0.02 % | $ 7.21 B | ||
|
Allscripts Healthcare Solutions
MDRX
|
594 M | - | -10.39 % | $ 886 M | ||
|
NextGen Healthcare
NXGN
|
653 M | - | - | $ 1.6 B | ||
|
iCAD
ICAD
|
19.6 M | - | - | $ 102 M | ||
|
HealthStream
HSTM
|
304 M | $ 27.03 | -2.19 % | $ 811 M | ||
|
OptimizeRx Corporation
OPRX
|
109 M | $ 7.33 | 5.62 % | $ 136 M | ||
|
American Well Corporation
AMWL
|
249 M | $ 11.11 | -0.8 % | $ 178 M | ||
|
Evolent Health
EVH
|
469 M | $ 3.98 | -14.94 % | $ 455 M | ||
|
GoodRx Holdings
GDRX
|
797 M | $ 3.37 | -3.03 % | $ 1.2 B | ||
|
Castlight Health, Inc.
CSLT
|
147 M | - | -7.28 % | $ 227 M | ||
|
HMS Holdings Corp.
HMSY
|
673 M | - | - | $ 3.29 B | ||
|
Inovalon Holdings, Inc.
INOV
|
668 M | - | - | $ 6.37 B | ||
|
Health Catalyst
HCAT
|
311 M | $ 1.28 | -6.57 % | $ 89.5 M | ||
|
HealthEquity
HQY
|
1.31 B | $ 97.31 | -4.45 % | $ 8.38 B | ||
|
Omnicell
OMCL
|
1.18 B | $ 34.77 | 2.25 % | $ 1.6 B | ||
|
Progyny
PGNY
|
318 M | $ 36.17 | -1.48 % | $ 3.08 B | ||
|
Veeva Systems
VEEV
|
3.2 B | $ 277.48 | -3.79 % | $ 45.4 B | ||
|
Schrödinger
SDGR
|
256 M | $ 27.15 | 5.79 % | $ 1.99 B | ||
|
So-Young International
SY
|
1.52 B | $ 1.83 | -5.67 % | $ 142 M | ||
|
SCWorx Corp.
WORX
|
2.88 M | $ 1.18 | 4.04 % | $ 8.58 M | ||
|
Zhongchao
ZCMD
|
11.4 M | $ 0.91 | 4.25 % | $ 3.11 M | ||
|
Teladoc Health
TDOC
|
2.53 B | $ 8.1 | -4.65 % | $ 1.43 B | ||
|
Computer Programs and Systems
CPSI
|
347 M | - | 4.4 % | $ 133 M | ||
|
Phreesia
PHR
|
481 M | $ 12.26 | -2.39 % | $ 732 M | ||
|
Akerna Corp.
KERN
|
185 M | - | - | $ 161 M | ||
|
MTBC
MTBC
|
120 M | - | -0.58 % | $ 51.7 M | ||
|
Premier
PINC
|
263 M | - | - | $ 2.33 B | ||
|
Streamline Health Solutions
STRM
|
17.9 M | - | - | $ 21.4 M |